Evaluation of bactericidal and anti-biofilm properties of a novel surface-active organosilane biocide against healthcare associated pathogens and Pseudomonas aeruginosa biolfilm

Jason Murray, Tendai Muruko, Chris IR Gill, Patricia Kearney, David Farren, Michael G Scott, Geoff McMullan, Nigel G Ternan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Healthcare acquired infections (HAI) pose a great threat in hospital settings and environmental contamination can be attributed to the spread of these. De-contamination and, significantly, prevention of re-contamination of the environment could help in preventing/reducing this threat. Goldshield (GS5) is a novel organosilane biocide marketed as a single application product with residual biocidal activity. We tested the hypothesis that GS5 could provide longer-term residual antimicrobial activity than existing disinfectants once applied to surfaces. Thus, the residual bactericidal properties of GS5, Actichlor and Distel against repeated challenge with Staphylococcus aureus ATCC43300 were tested, and showed that GS5 alone exhibited longer-term bactericidal activity for up to 6 days on 316I stainless steel surfaces. Having established efficacy against S. aureus, we tested GS5 against common healthcare acquired pathogens, and demonstrated that, on average, a 1 log10 bactericidal effect was exhibited by GS5 treated surfaces, although biocidal activity varied depending upon the surface type and the species of bacteria. The ability of GS5 to prevent Pseudomonas aeruginosa biofilm formation was measured in standard microtitre plate assays, where it had no significant effect on either biofilm formation or development. Taken together the data suggests that GS5 treatment of surfaces may be a useful means to reducing bacterial contamination in the context of infection control practices.
LanguageEnglish
JournalPLoS ONE
Volume12
Issue number8
DOIs
Publication statusPublished - 7 Aug 2017

Fingerprint

biocides
Disinfectants
Biofilms
Pathogens
Pseudomonas aeruginosa
biofilm
health services
Staphylococcus aureus
Delivery of Health Care
Contamination
pathogens
Stainless Steel
Infection Control
Bacteria
pollution
Infection
bacterial contamination
antibacterial properties
disinfectants
stainless steel

Keywords

  • biocide healthcare associated pathogens biofilm Pseudomonas organosilane

Cite this

@article{43ce0b64e3b549a383edd0de9576b43f,
title = "Evaluation of bactericidal and anti-biofilm properties of a novel surface-active organosilane biocide against healthcare associated pathogens and Pseudomonas aeruginosa biolfilm",
abstract = "Healthcare acquired infections (HAI) pose a great threat in hospital settings and environmental contamination can be attributed to the spread of these. De-contamination and, significantly, prevention of re-contamination of the environment could help in preventing/reducing this threat. Goldshield (GS5) is a novel organosilane biocide marketed as a single application product with residual biocidal activity. We tested the hypothesis that GS5 could provide longer-term residual antimicrobial activity than existing disinfectants once applied to surfaces. Thus, the residual bactericidal properties of GS5, Actichlor and Distel against repeated challenge with Staphylococcus aureus ATCC43300 were tested, and showed that GS5 alone exhibited longer-term bactericidal activity for up to 6 days on 316I stainless steel surfaces. Having established efficacy against S. aureus, we tested GS5 against common healthcare acquired pathogens, and demonstrated that, on average, a 1 log10 bactericidal effect was exhibited by GS5 treated surfaces, although biocidal activity varied depending upon the surface type and the species of bacteria. The ability of GS5 to prevent Pseudomonas aeruginosa biofilm formation was measured in standard microtitre plate assays, where it had no significant effect on either biofilm formation or development. Taken together the data suggests that GS5 treatment of surfaces may be a useful means to reducing bacterial contamination in the context of infection control practices.",
keywords = "biocide healthcare associated pathogens biofilm Pseudomonas organosilane",
author = "Jason Murray and Tendai Muruko and Gill, {Chris IR} and Patricia Kearney and David Farren and Scott, {Michael G} and Geoff McMullan and Ternan, {Nigel G}",
note = "Reference text: 1. Zingg W, Holmes A, Dettenkofer M, Goetting T, Secci F, Clack L, et al. Hospital organisation, management, and structure for prevention of health-care-associated infection: a systematic review and expert consensus. Lancet. Infect. Dis. 2015;15:212–224 2. Zimlichman E, Henderson D, Tamir O, Franz C, Song P, Yamin CK, et al. . Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med. 2013;173:2039–2046. 3. van Kleef E, Robotham J V, Jit M, Deeny SR, Edmunds WJ. Modelling the transmission of healthcare associated infections: a systematic review. BMC Infect. Dis. 2013;13:294 4. Wagenvoort JH, Sluijsmans W, Penders RJ. Better environmental survival of outbreak vs. sporadic MRSA isolates. J. Hosp. Infect. 2000;45:231–234 5. Otter JA, Yezli S, Salkeld JAG, French GL. Evidence that contaminated surfaces contribute to the transmission of hospital pathogens and an overview of strategies to address contaminated surfaces in hospital settings. Am. J. Infect. Control. 2013;41:S6–11 6. Wagenvoort JHT, De Brauwer EIGB, Penders RJR, Willems RJ, Top J, Bonten MJ. Environmental survival of vancomycin-resistant Enterococcus faecium. J. Hosp. Infect. 2011;77:282–283 7. Thomas E, B{\'e}mer P, Eckert C, Guillouzouic A, Orain J, Corvec S, et al. Clostridium difficile infections: analysis of recurrence in an area with low prevalence of 027 strain. J. Hosp. Infect. 2016. 8. Abdallah M, Benoliel C, Drider D, Dhulster P, Chihib N-E. Biofilm formation and persistence on abiotic surfaces in the context of food and medical environments. Arch. Microbiol., vol. 196, no. 7, pp. 453–472, Jul. 2014. 9. Walker JT, Jhutty A, Parks S, Willis C, Copley V, Turton JF, et al. Investigation of healthcare-acquired infections associated with Pseudomonas aeruginosa biofilms in taps in neonatal units in Northern Ireland. J. Hosp. Infect. 2014;86:16–23 10. Hota B. Contamination, disinfection, and cross-colonization: are hospital surfaces reservoirs for nosocomial infection? Clin. Infect. Dis. 2004;39:1182–1189 11. French GL, Otter JA, Shannon KP, Adams NMT, Watling D, Parks MJ. Tackling contamination of the hospital environment by methicillin-resistant Staphylococcus aureus (MRSA): a comparison between conventional terminal cleaning and hydrogen peroxide vapour decontamination. J. Hosp. Infect. 2004;57:31–33 12. Beggs C, Knibbs LD, Johnson GR, Morawska L. Environmental contamination and hospital-acquired infection: factors that are easily overlooked. Indoor Air. 2015;25:462–474 13. Ramphal L, Suzuki S, McCracken IM, Addai A. Improving hospital staff compliance with environmental cleaning behavior. Proc. (Bayl. Univ. Med. Cent). 2014;27:88–91 14. Hardy KJ, Oppenheim BA, Gossain S, Gao F, Hawkey PM. A study of the relationship between environmental contamination with methicillin-resistant Staphylococcus aureus (MRSA) and patients’ acquisition of MRSA. Infect. Control Hosp. Epidemiol. 2006;27:127–132 15. Abreu AC, Tavares RR, Borges A, Mergulh{\~a}o F, Sim{\~o}es M. Current and emergent strategies for disinfection of hospital environments. J. Antimicrob. Chemother. 2013;68:2718–2732 16. Aldeyab MA, Mcelnay JC, Elshibly SM, Hughes CM, Mcdowell DA, McMahon MAS, et al. Evaluation of the Efficacy of a Conventional Cleaning Regimen in Removing Methicillin ‐ Resistant Staphylococcus aureus From Contaminated Surfaces in an Intensive Care Unit. Infect Control Hosp Epidemiol. 2009;30(3):304-306. 17. Muller MP, MacDougall C, Lim M. Antimicrobial surfaces to prevent healthcare-associated infections: a systematic review. J. Hosp. Infect. 2015;92:7–13 18. Diseases and Organisms in Healthcare Settings. U.S. Centers for Disease Control and Prevention Website. http://www.cdc.gov/HAI/organisms/organisms.html. Published 2014. Accessed 08 March 2016. 19. Altaf M, Miller CH, Bellows DS, O’Toole R. Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors. Tuberculosis (Edinb). 2010;90:333–337 20. Baxa D, Shetron-Rama L, Golembieski M, Golembieski M, Jain S, Gordon M, et al. In vitro evaluation of a novel process for reducing bacterial contamination of environmental surfaces. Am. J. Infect. Control. 2011;39:483–487 21. Djordjevic D, Wiedmann M, McLandsborough LA. Microtiter Plate Assay for Assessment of Listeria monocytogenes Biofilm Formation. Appl. Environ. Microbiol. 2002;68:2950–2958 22. O’Toole, GA. Microtitre Dish Biofilm Formation Assay. JoVE. 2011;47:2437. 23. Shen Y, K{\"o}ller T, Kreikemeyer B, Nelson DC. Rapid degradation of Streptococcus pyogenes biofilms by PlyC, a bacteriophage-encoded endolysin. J. Antimicrob. Chemother. 2013;68:1818–1824 24. Webb JS, Thompson LS, James S, Charlton T, Tolker-Nielsen T, Koch B, et al. Cell Death in Pseudomonas aeruginosa Biofilm Development. J. Bacteriol. 2003;185:4585–4592 25. Bauer J, Siala W, Tulkens PM, Van Bambeke F. A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms. Antimicrob. Agents Chemother. 2013;57:2726–2737 26. Whitchurch CB, Tolker-Nielsen T, Ragas, PC, Mattick, JS. Extracellular DNA Required for Bacterial Biofilm Formation. Science. 2002;295(5559):148727. Otter JA, Vickery K, Walker JT, deLancey Pulcini E, Stoodley P, Goldenberg SD, et al. Surface-attached cells, biofilms and biocide susceptibility: implications for hospital cleaning and disinfection. J Hosp Infect. 2015;89(1):16–27. 28. Percival SL, Suleman L, Vuotto C, Donelli G. Healthcare-associated infections, medical devices and biofilms: risk, tolerance and control. J Med Microbiol. 2015;64(4):323-334. 29. Devlin-Mullin A, Todd NM, Golrokhi Z, Geng H, Konerding MA, Ternan NG, et al. Atomic Layer Deposition of a Silver Nanolayer on Advanced Titanium Orthopedic Implants Inhibits Bacterial Colonization and Supports Vascularized de Novo Bone Ingrowth. Adv Healthc Mater. 2017;6(11). 30. Bayles KW. The biological role of death and lysis in biofilm development. Nature Rev. Microbiol. 2007;5:721-726",
year = "2017",
month = "8",
day = "7",
doi = "10.1371/journal.pone.0182624",
language = "English",
volume = "12",
journal = "PLoS ONE",
issn = "1932-6203",
number = "8",

}

Evaluation of bactericidal and anti-biofilm properties of a novel surface-active organosilane biocide against healthcare associated pathogens and Pseudomonas aeruginosa biolfilm. / Murray, Jason; Muruko, Tendai; Gill, Chris IR; Kearney, Patricia; Farren, David; Scott, Michael G; McMullan, Geoff; Ternan, Nigel G.

In: PLoS ONE, Vol. 12, No. 8, 07.08.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation of bactericidal and anti-biofilm properties of a novel surface-active organosilane biocide against healthcare associated pathogens and Pseudomonas aeruginosa biolfilm

AU - Murray, Jason

AU - Muruko, Tendai

AU - Gill, Chris IR

AU - Kearney, Patricia

AU - Farren, David

AU - Scott, Michael G

AU - McMullan, Geoff

AU - Ternan, Nigel G

N1 - Reference text: 1. Zingg W, Holmes A, Dettenkofer M, Goetting T, Secci F, Clack L, et al. Hospital organisation, management, and structure for prevention of health-care-associated infection: a systematic review and expert consensus. Lancet. Infect. Dis. 2015;15:212–224 2. Zimlichman E, Henderson D, Tamir O, Franz C, Song P, Yamin CK, et al. . Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med. 2013;173:2039–2046. 3. van Kleef E, Robotham J V, Jit M, Deeny SR, Edmunds WJ. Modelling the transmission of healthcare associated infections: a systematic review. BMC Infect. Dis. 2013;13:294 4. Wagenvoort JH, Sluijsmans W, Penders RJ. Better environmental survival of outbreak vs. sporadic MRSA isolates. J. Hosp. Infect. 2000;45:231–234 5. Otter JA, Yezli S, Salkeld JAG, French GL. Evidence that contaminated surfaces contribute to the transmission of hospital pathogens and an overview of strategies to address contaminated surfaces in hospital settings. Am. J. Infect. Control. 2013;41:S6–11 6. Wagenvoort JHT, De Brauwer EIGB, Penders RJR, Willems RJ, Top J, Bonten MJ. Environmental survival of vancomycin-resistant Enterococcus faecium. J. Hosp. Infect. 2011;77:282–283 7. Thomas E, Bémer P, Eckert C, Guillouzouic A, Orain J, Corvec S, et al. Clostridium difficile infections: analysis of recurrence in an area with low prevalence of 027 strain. J. Hosp. Infect. 2016. 8. Abdallah M, Benoliel C, Drider D, Dhulster P, Chihib N-E. Biofilm formation and persistence on abiotic surfaces in the context of food and medical environments. Arch. Microbiol., vol. 196, no. 7, pp. 453–472, Jul. 2014. 9. Walker JT, Jhutty A, Parks S, Willis C, Copley V, Turton JF, et al. Investigation of healthcare-acquired infections associated with Pseudomonas aeruginosa biofilms in taps in neonatal units in Northern Ireland. J. Hosp. Infect. 2014;86:16–23 10. Hota B. Contamination, disinfection, and cross-colonization: are hospital surfaces reservoirs for nosocomial infection? Clin. Infect. Dis. 2004;39:1182–1189 11. French GL, Otter JA, Shannon KP, Adams NMT, Watling D, Parks MJ. Tackling contamination of the hospital environment by methicillin-resistant Staphylococcus aureus (MRSA): a comparison between conventional terminal cleaning and hydrogen peroxide vapour decontamination. J. Hosp. Infect. 2004;57:31–33 12. Beggs C, Knibbs LD, Johnson GR, Morawska L. Environmental contamination and hospital-acquired infection: factors that are easily overlooked. Indoor Air. 2015;25:462–474 13. Ramphal L, Suzuki S, McCracken IM, Addai A. Improving hospital staff compliance with environmental cleaning behavior. Proc. (Bayl. Univ. Med. Cent). 2014;27:88–91 14. Hardy KJ, Oppenheim BA, Gossain S, Gao F, Hawkey PM. A study of the relationship between environmental contamination with methicillin-resistant Staphylococcus aureus (MRSA) and patients’ acquisition of MRSA. Infect. Control Hosp. Epidemiol. 2006;27:127–132 15. Abreu AC, Tavares RR, Borges A, Mergulhão F, Simões M. Current and emergent strategies for disinfection of hospital environments. J. Antimicrob. Chemother. 2013;68:2718–2732 16. Aldeyab MA, Mcelnay JC, Elshibly SM, Hughes CM, Mcdowell DA, McMahon MAS, et al. Evaluation of the Efficacy of a Conventional Cleaning Regimen in Removing Methicillin ‐ Resistant Staphylococcus aureus From Contaminated Surfaces in an Intensive Care Unit. Infect Control Hosp Epidemiol. 2009;30(3):304-306. 17. Muller MP, MacDougall C, Lim M. Antimicrobial surfaces to prevent healthcare-associated infections: a systematic review. J. Hosp. Infect. 2015;92:7–13 18. Diseases and Organisms in Healthcare Settings. U.S. Centers for Disease Control and Prevention Website. http://www.cdc.gov/HAI/organisms/organisms.html. Published 2014. Accessed 08 March 2016. 19. Altaf M, Miller CH, Bellows DS, O’Toole R. Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors. Tuberculosis (Edinb). 2010;90:333–337 20. Baxa D, Shetron-Rama L, Golembieski M, Golembieski M, Jain S, Gordon M, et al. In vitro evaluation of a novel process for reducing bacterial contamination of environmental surfaces. Am. J. Infect. Control. 2011;39:483–487 21. Djordjevic D, Wiedmann M, McLandsborough LA. Microtiter Plate Assay for Assessment of Listeria monocytogenes Biofilm Formation. Appl. Environ. Microbiol. 2002;68:2950–2958 22. O’Toole, GA. Microtitre Dish Biofilm Formation Assay. JoVE. 2011;47:2437. 23. Shen Y, Köller T, Kreikemeyer B, Nelson DC. Rapid degradation of Streptococcus pyogenes biofilms by PlyC, a bacteriophage-encoded endolysin. J. Antimicrob. Chemother. 2013;68:1818–1824 24. Webb JS, Thompson LS, James S, Charlton T, Tolker-Nielsen T, Koch B, et al. Cell Death in Pseudomonas aeruginosa Biofilm Development. J. Bacteriol. 2003;185:4585–4592 25. Bauer J, Siala W, Tulkens PM, Van Bambeke F. A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms. Antimicrob. Agents Chemother. 2013;57:2726–2737 26. Whitchurch CB, Tolker-Nielsen T, Ragas, PC, Mattick, JS. Extracellular DNA Required for Bacterial Biofilm Formation. Science. 2002;295(5559):148727. Otter JA, Vickery K, Walker JT, deLancey Pulcini E, Stoodley P, Goldenberg SD, et al. Surface-attached cells, biofilms and biocide susceptibility: implications for hospital cleaning and disinfection. J Hosp Infect. 2015;89(1):16–27. 28. Percival SL, Suleman L, Vuotto C, Donelli G. Healthcare-associated infections, medical devices and biofilms: risk, tolerance and control. J Med Microbiol. 2015;64(4):323-334. 29. Devlin-Mullin A, Todd NM, Golrokhi Z, Geng H, Konerding MA, Ternan NG, et al. Atomic Layer Deposition of a Silver Nanolayer on Advanced Titanium Orthopedic Implants Inhibits Bacterial Colonization and Supports Vascularized de Novo Bone Ingrowth. Adv Healthc Mater. 2017;6(11). 30. Bayles KW. The biological role of death and lysis in biofilm development. Nature Rev. Microbiol. 2007;5:721-726

PY - 2017/8/7

Y1 - 2017/8/7

N2 - Healthcare acquired infections (HAI) pose a great threat in hospital settings and environmental contamination can be attributed to the spread of these. De-contamination and, significantly, prevention of re-contamination of the environment could help in preventing/reducing this threat. Goldshield (GS5) is a novel organosilane biocide marketed as a single application product with residual biocidal activity. We tested the hypothesis that GS5 could provide longer-term residual antimicrobial activity than existing disinfectants once applied to surfaces. Thus, the residual bactericidal properties of GS5, Actichlor and Distel against repeated challenge with Staphylococcus aureus ATCC43300 were tested, and showed that GS5 alone exhibited longer-term bactericidal activity for up to 6 days on 316I stainless steel surfaces. Having established efficacy against S. aureus, we tested GS5 against common healthcare acquired pathogens, and demonstrated that, on average, a 1 log10 bactericidal effect was exhibited by GS5 treated surfaces, although biocidal activity varied depending upon the surface type and the species of bacteria. The ability of GS5 to prevent Pseudomonas aeruginosa biofilm formation was measured in standard microtitre plate assays, where it had no significant effect on either biofilm formation or development. Taken together the data suggests that GS5 treatment of surfaces may be a useful means to reducing bacterial contamination in the context of infection control practices.

AB - Healthcare acquired infections (HAI) pose a great threat in hospital settings and environmental contamination can be attributed to the spread of these. De-contamination and, significantly, prevention of re-contamination of the environment could help in preventing/reducing this threat. Goldshield (GS5) is a novel organosilane biocide marketed as a single application product with residual biocidal activity. We tested the hypothesis that GS5 could provide longer-term residual antimicrobial activity than existing disinfectants once applied to surfaces. Thus, the residual bactericidal properties of GS5, Actichlor and Distel against repeated challenge with Staphylococcus aureus ATCC43300 were tested, and showed that GS5 alone exhibited longer-term bactericidal activity for up to 6 days on 316I stainless steel surfaces. Having established efficacy against S. aureus, we tested GS5 against common healthcare acquired pathogens, and demonstrated that, on average, a 1 log10 bactericidal effect was exhibited by GS5 treated surfaces, although biocidal activity varied depending upon the surface type and the species of bacteria. The ability of GS5 to prevent Pseudomonas aeruginosa biofilm formation was measured in standard microtitre plate assays, where it had no significant effect on either biofilm formation or development. Taken together the data suggests that GS5 treatment of surfaces may be a useful means to reducing bacterial contamination in the context of infection control practices.

KW - biocide healthcare associated pathogens biofilm Pseudomonas organosilane

U2 - 10.1371/journal.pone.0182624

DO - 10.1371/journal.pone.0182624

M3 - Article

VL - 12

JO - PLoS ONE

T2 - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 8

ER -